A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis

Inclusion Criteria

• •Patients aged ≥18 years
• •Confirmed diagnosis of AD by dermatologist prior to study inclusion
• •Patient for whom the decision to initiate treatment with abrocitinib was made as part of routine clinical practice irrespective of the patients being
• •1. abrocitinib naive or,
• •2. patients who reinitialize treatment with abrocitinib after being off treatment for ≥28 days prior to study inclusion
• •Patient is eligible for abrocitinib treatment according to Summary of Product Characteristics (SmPC)
• •Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the non-interventional study